Boston Scientific (BSX) Stock Forecast & Price Target

Compare

3,994 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BSX Analyst Ratings

Strong Buy

22 Buy

0 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Boston

Scientific

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BSX Stock 12 Month Forecast

Average Price Target

$124.33

▲(41.18% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $124.33 with a high forecast of $140.00 and a low forecast of $100.00. The average price target represents a 41.18% change from the last price of $88.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"$88","141":"$141","101.25":"$101.3","114.5":"$114.5","127.75":"$127.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":124.33333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$124.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,101.25,114.5,127.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.35,98.78461538461538,102.21923076923076,105.65384615384615,109.08846153846153,112.52307692307691,115.9576923076923,119.3923076923077,122.82692307692307,126.26153846153846,129.69615384615383,133.13076923076923,136.56538461538463,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.35,97.57948717948717,99.80897435897435,102.03846153846153,104.26794871794871,106.49743589743589,108.72692307692307,110.95641025641025,113.18589743589743,115.41538461538461,117.64487179487179,119.87435897435897,122.10384615384615,{"y":124.33333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.35,95.7076923076923,96.06538461538462,96.42307692307692,96.78076923076922,97.13846153846154,97.49615384615385,97.85384615384615,98.21153846153845,98.56923076923077,98.92692307692307,99.28461538461538,99.6423076923077,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":89.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.01,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$140.00

Average Price Target$124.33

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rick Wise

Stifel Nicolaus

$125

Buy

41.93%

Upside

Reiterated

01/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (NASDAQ: TMDX), Beam Therapeutics (NASDAQ: BEAM) and Boston Scientific (NYSE: BSX)

Travis Steed

Bank of America Securities

$120

Buy

36.26%

Upside

Reiterated

01/19/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Atea Pharmaceuticals (NASDAQ: AVIR) and Penumbra (NYSE: PEN)

Richard Newitter

Truist Financial

$120

Buy

36.26%

Upside

Reiterated

01/16/26

Analysts Are Bullish on Top Healthcare Stocks: Prestige Consumer Healthcare (PBH), Boston Scientific (BSX)

Suraj Kalia

Oppenheimer

$125→$100

Buy

13.55%

Upside

Reiterated

01/16/26

Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX)

Matt Miksic

Barclays

$136

Buy

54.42%

Upside

Reiterated

01/16/26

Barclays Sticks to Its Buy Rating for Boston Scientific (BSX)

Josh Jennings

TD Cowen

$115

Buy

30.58%

Upside

Reiterated

01/16/26

Boston Scientific: Undervalued Ahead of Strong Q4 Results, 2026 Outlook, and PEN Acquisition Catalyst

Michael Matson

Needham

$121

Buy

37.39%

Upside

Reiterated

01/15/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Marie Thibault

BTIG

$132

Buy

49.88%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Bruker (NASDAQ: BRKR)

Joanne Wuensch

Citi

$130

Buy

47.61%

Upside

Reiterated

01/13/26

Boston Scientific: Diversified Growth Engines and Strong Execution Underpin Reiterated Buy Rating

Lee Hambright

Bernstein

$130

Buy

47.61%

Upside

Reiterated

01/13/26

Bernstein Reaffirms Their Buy Rating on Boston Scientific (BSX)

Shagun Singh Chadha

RBC Capital

$130

Buy

47.61%

Upside

Reiterated

01/12/26

RBC Capital Keeps Their Buy Rating on Boston Scientific (BSX)

David Roman

Goldman Sachs

$124→$112

Buy

27.17%

Upside

Reiterated

01/09/26

Boston Scientific price target lowered to $112 from $124 at Goldman SachsBoston Scientific price target lowered to $112 from $124 at Goldman Sachs

Vijay Kumar

Evercore ISI

$113→$112

Buy

27.17%

Upside

Reiterated

01/05/26

Boston Scientific price target lowered to $112 from $113 at Evercore ISIBoston Scientific price target lowered to $112 from $113 at Evercore ISI

Robbie Marcus

J.P. Morgan

Buy

―

Reiterated

12/18/25

J.P. Morgan Sticks to Their Buy Rating for Boston Scientific (BSX)

William Plovanic

Canaccord Genuity

$132→$131

Buy

48.75%

Upside

Reiterated

12/17/25

Boston Scientific price target lowered to $131 from $132 at CanaccordBoston Scientific price target lowered to $131 from $132 at Canaccord

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rick Wise

Stifel Nicolaus

$125

Buy

41.93%

Upside

Reiterated

01/20/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (NASDAQ: TMDX), Beam Therapeutics (NASDAQ: BEAM) and Boston Scientific (NYSE: BSX)

Travis Steed

Bank of America Securities

$120

Buy

36.26%

Upside

Reiterated

01/19/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Atea Pharmaceuticals (NASDAQ: AVIR) and Penumbra (NYSE: PEN)

Richard Newitter

Truist Financial

$120

Buy

36.26%

Upside

Reiterated

01/16/26

Analysts Are Bullish on Top Healthcare Stocks: Prestige Consumer Healthcare (PBH), Boston Scientific (BSX)

Suraj Kalia

Oppenheimer

$125→$100

Buy

13.55%

Upside

Reiterated

01/16/26

Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX)

Matt Miksic

Barclays

$136

Buy

54.42%

Upside

Reiterated

01/16/26

Barclays Sticks to Its Buy Rating for Boston Scientific (BSX)

Josh Jennings

TD Cowen

$115

Buy

30.58%

Upside

Reiterated

01/16/26

Boston Scientific: Undervalued Ahead of Strong Q4 Results, 2026 Outlook, and PEN Acquisition Catalyst

Michael Matson

Needham

$121

Buy

37.39%

Upside

Reiterated

01/15/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Marie Thibault

BTIG

$132

Buy

49.88%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Bruker (NASDAQ: BRKR)

Joanne Wuensch

Citi

$130

Buy

47.61%

Upside

Reiterated

01/13/26

Boston Scientific: Diversified Growth Engines and Strong Execution Underpin Reiterated Buy Rating

Lee Hambright

Bernstein

$130

Buy

47.61%

Upside

Reiterated

01/13/26

Bernstein Reaffirms Their Buy Rating on Boston Scientific (BSX)

Shagun Singh Chadha

RBC Capital

$130

Buy

47.61%

Upside

Reiterated

01/12/26

RBC Capital Keeps Their Buy Rating on Boston Scientific (BSX)

David Roman

Goldman Sachs

$124→$112

Buy

27.17%

Upside

Reiterated

01/09/26

Boston Scientific price target lowered to $112 from $124 at Goldman SachsBoston Scientific price target lowered to $112 from $124 at Goldman Sachs

Vijay Kumar

Evercore ISI

$113→$112

Buy

27.17%

Upside

Reiterated

01/05/26

Boston Scientific price target lowered to $112 from $113 at Evercore ISIBoston Scientific price target lowered to $112 from $113 at Evercore ISI

Robbie Marcus

J.P. Morgan

Buy

―

Reiterated

12/18/25

J.P. Morgan Sticks to Their Buy Rating for Boston Scientific (BSX)

William Plovanic

Canaccord Genuity

$132→$131

Buy

48.75%

Upside

Reiterated

12/17/25

Boston Scientific price target lowered to $131 from $132 at CanaccordBoston Scientific price target lowered to $131 from $132 at Canaccord

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

3 Months

xxx

Success Rate

33/41 ratings generated profit

Average Return

+6.46%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.49% of your transactions generating a profit, with an average return of +6.46% per trade.

1 Year

Richard NewitterTruist Financial

Success Rate

22/26 ratings generated profit

Average Return

+26.98%

reiterated a buy rating 5 days ago

Copying Richard Newitter's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +26.98% per trade.

2 Years

xxx

Success Rate

26/30 ratings generated profit

Average Return

+41.76%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.67% of your transactions generating a profit, with an average return of +41.76% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BSX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BSX has received 35 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BSX average Analyst price target in the past 3 months is 124.33.

Each month's total comprises the sum of three months' worth of ratings.

BSX Financial Forecast

BSX Earnings Forecast

Next quarter’s earnings estimate for BSX is $0.78 with a range of $0.77 to $0.81. The previous quarter’s EPS was $0.75. BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Sales Forecast

Next quarter’s sales forecast for BSX is $5.28B with a range of $5.25B to $5.33B. The previous quarter’s sales results were $5.07B. BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BSX has Performed in-line its overall industry.

BSX Stock Forecast FAQ

What is BSX’s average 12-month price target, according to analysts?

Based on analyst ratings, Boston Scientific’s 12-month average price target is 124.33.

What is BSX’s upside potential, based on the analysts’ average price target?

Boston Scientific has 41.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BSX a Buy, Sell or Hold?

Boston Scientific has a consensus rating of Strong Buy which is based on 22 buy ratings, 0 hold ratings and 0 sell ratings.

What is Boston Scientific’s price target?

The average price target for Boston Scientific is 124.33. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $100.00. The average price target represents 41.18% Increase from the current price of $88.07.

What do analysts say about Boston Scientific?

Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of BSX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Boston Scientific (BSX) Stock Forecast & Price Target

BSX Analyst Ratings

BSX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Boston Scientific

BSX Analyst Recommendation Trends

BSX Financial Forecast

BSX Earnings Forecast

BSX Sales Forecast

BSX Stock Forecast FAQ

Detailed List of Analyst Forecasts